Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Takaji Wakita and Shingo Iwami.
Takaji Wakita
Connection Strength
0.886
Shingo Iwami
  1. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med. 2021 07; 18(7):e1003660.
    View in: PubMed
    Score: 0.239
  2. Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. J R Soc Interface. 2021 04; 18(177):20200947.
    View in: PubMed
    Score: 0.235
  3. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience. 2021 Apr 23; 24(4):102367.
    View in: PubMed
    Score: 0.234
  4. Revisiting the guidelines for ending isolation for COVID-19 patients. Elife. 2021 07 27; 10.
    View in: PubMed
    Score: 0.060
  5. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Front Microbiol. 2021; 12:651403.
    View in: PubMed
    Score: 0.059
  6. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial. Trials. 2021 Apr 28; 22(1):309.
    View in: PubMed
    Score: 0.059
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.